Analytical Data
-
Gene name
VSIG8
- Application
-
Alternative Names
VSIG8；C1orf204；V-set and immunoglobulin domain-containing Protein 8
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5VU13
-
Expression Region
22-263aa
-
AA Sequence
VRINGDGQE VLYLAEGDNV RLGCPYVLDP EDYGPNGLDI EWMQVNSDPA HHRENVFLSY QDKRINHGSL PHLQQRVRFA ASDPSQYDAS INLMNLQVSD TATYECRVKK TTMATRKVIV TVQARPAVPM CWTEGHMTYG NDVVLKCYAS GGSQPLSYKW AKISGHHYPY RAGSYTSQHS YHSELSYQES FHSSINQGLN NGDLVLKDIS RADDGLYQCT VANNVGYSVC VVEVKVSDSR RIG
-
Molecular Weight
29 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VSIG8 (V-set and immunoglobulin domain containing 8) is a member of the immunoglobulin superfamily and has emerged as a significant focus in immunology and cancer research. Initially identified in the context of immune system regulation, VSIG8 is expressed in various immune cells, suggesting a role in modulating immune responses. Recent studies have highlighted its potential as a co-regulator in T cell activation and tolerance, indicating its involvement in both autoimmune diseases and cancer immunotherapy. In cancer, VSIG8 has been associated with tumor progression and immune evasion, as tumors often exploit immune checkpoints to avoid detection and destruction by the immune system. The understanding of VSIG8's molecular mechanisms could pave the way for new therapeutic strategies aimed at enhancing anti-tumor immunity. Moreover, VSIG8’s expression patterns in different tissues and tumors reveal its potential as a biomarker for cancer diagnosis and prognosis. Ongoing research into recombinant VSIG8 proteins aims to elucidate its structure-function relationship and interactions with other immune modulators, which could ultimately contribute to developing novel immunotherapeutic approaches. In summary, the investigation of VSIG8 recombinant proteins holds great promise for advancing our understanding of immune regulation and improving cancer treatment outcomes.
